United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group
- PMID: 9454524
- DOI: 10.7326/0003-4819-128-3-199802010-00001
United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group
Abstract
Background: Uncertainty exists about the suitability of oral hypoglycemic drugs and insulin therapy for patients with newly diagnosed type 2 diabetes.
Objective: To assess and compare response to sulfonylurea, insulin, or metformin over 6 years in patients with newly diagnosed type 2 diabetes in whom disease could and could not be controlled with diet therapy alone.
Design: Multicenter, randomized, controlled trial.
Setting: Outpatient diabetes clinics of 15 hospitals in the United Kingdom.
Intervention: Sulfonylurea (chlorpropamide or glyburide), insulin, or metformin (if patients were obese).
Patients: 458 patients with newly diagnosed type 2 diabetes that could not be controlled with diet and had hyperglycemic symptoms or fasting plasma glucose levels greater than 15 mmol/L during the initial 3 months of diet therapy (primary diet failure group) and 1620 patients in whom disease was controlled by diet therapy and who had fasting plasma glucose levels of 6 to 15 mmol/L and no hyperglycemic symptoms while receiving diet therapy alone.
Measurements: Fasting plasma levels of glucose and insulin, hemoglobin A1c concentrations, body weight, and therapy required.
Results: Compared with the diet-controlled group, the primary diet failure group was younger and less obese and had more retinopathy, lower fasting plasma insulin levels, and reduced beta-cell function. At 6 years, patients allocated to insulin had lower fasting plasma glucose levels than did patients allocated to oral agents, but hemoglobin A1c concentrations were similar. Forty-eight percent (95% CI, 37% to 58%) of patients in the primary diet failure group maintained hemoglobin A1c concentrations less than 0.08. By 6 years, 51% of patients (CI, 42% to 62%) allocated to ultralente insulin required additional short-acting insulin and 66% of patients (CI, 58% to 73%) allocated to sulfonylurea required additional therapy with metformin or insulin to control symptoms and maintain fasting plasma glucose levels less than 15 mmol/L. Patients allocated to insulin gained more weight and had more hypoglycemic attacks than did patients allocated to sulfonylurea. Obese patients allocated to metformin gained the least weight and had the fewest hypoglycemic attacks. For all therapies, control achieved at 6 years was worse in the primary diet failure group than in the diet-controlled group.
Conclusions: Because initial insulin therapy induced more hypoglycemic reactions and weight gain without necessarily providing better control, it may be reasonable to start with oral agents and change to insulin if goals for glycemic levels are not achieved.
Comment in
- ACP J Club. 1998 Jul-Aug;129(1):12
Similar articles
-
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.JAMA. 1999 Jun 2;281(21):2005-12. doi: 10.1001/jama.281.21.2005. JAMA. 1999. PMID: 10359389 Clinical Trial.
-
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.BMJ. 1995 Jan 14;310(6972):83-8. BMJ. 1995. PMID: 7833731 Free PMC article. Clinical Trial.
-
UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.Diabetes Care. 1998 Jan;21(1):87-92. doi: 10.2337/diacare.21.1.87. Diabetes Care. 1998. PMID: 9538975 Clinical Trial.
-
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.Cochrane Database Syst Rev. 2016 Oct 17;10(10):CD012151. doi: 10.1002/14651858.CD012151.pub2. Cochrane Database Syst Rev. 2016. PMID: 27749986 Free PMC article. Review.
-
Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.Ann Intern Med. 2011 May 17;154(10):672-9. doi: 10.7326/0003-4819-154-10-201105170-00007. Ann Intern Med. 2011. PMID: 21576535 Review.
Cited by
-
The efficacy of switching basal-bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching.Diabetol Int. 2023 Sep 4;15(1):99-108. doi: 10.1007/s13340-023-00651-z. eCollection 2024 Jan. Diabetol Int. 2023. PMID: 38264217
-
A Daunting and Challenging Task to Prove the Effectiveness of Reducing Acute Exacerbation in COPD Patients with Type 2 Diabetes by GLP-1 Receptor Agonists.Am J Respir Crit Care Med. 2023 Dec 15;208(12):1345-1346. doi: 10.1164/rccm.202309-1671LE. Am J Respir Crit Care Med. 2023. PMID: 37855726 Free PMC article. No abstract available.
-
Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.Biomedicines. 2023 Mar 13;11(3):869. doi: 10.3390/biomedicines11030869. Biomedicines. 2023. PMID: 36979848 Free PMC article.
-
Dietary Fiber Intake Is Related to Skeletal Muscle Mass, Body Fat Mass, and Muscle-to-Fat Ratio Among People With Type 2 Diabetes: A Cross-Sectional Study.Front Nutr. 2022 May 31;9:881877. doi: 10.3389/fnut.2022.881877. eCollection 2022. Front Nutr. 2022. PMID: 35711555 Free PMC article.
-
[Physical and psychological long-term consequences of diabetes mellitus].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Apr;65(4):503-510. doi: 10.1007/s00103-022-03517-y. Epub 2022 Mar 16. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022. PMID: 35294561 Free PMC article. Review. German.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical